ANZUP 2017 Interviews - David Quinn
Nov 29, 2017•16 min
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
David Quinn discusses the KEYNOTE-045 trial on the benefits of pembrolizumab in second line treatment of advanced bladder cancer
For the best experience, listen in Metacast app for iOS or Android